The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.a

Pneumonitis (interstitial lung disease/ILD)

Cross-reaction has been reported with ILD from both lorlatinib and brigatinib in the same patient (PMID 31668321)

Publications

Li H, Wang C, Guo C

Post-marketing safety of lorlatinib: a real-world study based on the FDA adverse event reporting system.

Frontiers in pharmacology 2024;15;1385036 — 2024 — 1385036

Harrison PK, Boland HE, Aherne NJ, Palmieri DJ

An Unusual Case of Lorlatinib-Induced Pneumonitis: A Case Report.

Case reports in oncology 2022 Jan-Apr;15;225-230 — 2022 Jan-Apr — 225-230

Sharma S, Kommineni K, Mehta SS, Singh H

Lorlatinib-Associated Acute Respiratory Distress Syndrome.

American journal of therapeutics 2020 Jan 24;; — 2020 Jan 24

Monzonís X, Arriola E

Early Onset Pulmonary Toxicity With Lorlatinib in a Patient With Previous Pulmonary Toxicity From Brigatinib.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2019 Nov;14;e247-e248 — 2019 Nov — e247-e248

Pellegrino B, Facchinetti F, Bordi P, Silva M, Gnetti L, Tiseo M

Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature.

Clinical lung cancer 2018 03;19;e151-e161 — 2018 03 — e151-e161